Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

GlobeNewswire April 6, 2015

Curis to Present at the 27th Annual Roth Conference

GlobeNewswire March 3, 2015

Curis Announces Closing of Public Offering of Common Stock

GlobeNewswire March 2, 2015

Curis to Present at the Cowen and Company 35th Annual Health Care Conference

GlobeNewswire February 26, 2015

Curis Prices Public Offering of Common Stock

GlobeNewswire February 25, 2015

Curis Announces Proposed Public Offering of Common Stock

GlobeNewswire February 24, 2015

Curis Reports Fourth Quarter and Year-End 2014 Financial Results

GlobeNewswire February 24, 2015

Curis to Present at the 2015 Bio CEO and Investor Conference

GlobeNewswire February 3, 2015

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

GlobeNewswire January 21, 2015

Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors

GlobeNewswire December 18, 2014

Curis to Present at Upcoming Investor Conferences

GlobeNewswire November 26, 2014

Curis to Present at the Stifel 2014 Healthcare Conference

GlobeNewswire November 12, 2014

Curis Reports Third Quarter 2014 Financial Results and Pipeline Update

GlobeNewswire November 10, 2014

Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014

GlobeNewswire November 3, 2014

Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule

GlobeNewswire October 28, 2014

Curis to Present at the 13th Annual BIO Investor Forum

GlobeNewswire October 3, 2014

Curis Announces CUDC-907 Development Program Advancements

GlobeNewswire October 2, 2014

Curis to Present at Upcoming Investor Conferences

GlobeNewswire August 27, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Curis Reports Second Quarter 2014 Financial Results

GlobeNewswire August 7, 2014